- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-4 Registration of securities issued in business combination transactions
- 4.2 First Supplemental Indenture - Penwest Pharmaceuticals Co.
- 4.3 Second Supplemental Indenture - Generics Bidco I, LLC
- 4.4 Third Supplemental Indenture - Ledgemont Royalty Sub LLC
- 4.5 Fourth Supplemental Indenture - Vintage Pharmaceuticals, LLC
- 4.6 Fifth Supplemental Indenture - American Medical Systems Holdings, Inc.
- 4.7 Sixth Supplemental Indenture - American Medical Systems, Inc.
- 4.8 Seventh Supplemental Indenture - Generics Bidco II, LLC
- 4.11 First Supplemental Indenture - American Medical Systems Holdings, Inc.
- 4.12 Second Supplemental Indenture - American Medical Systems, Inc.
- 4.13 Third Supplemental Indenture - Generics Bidco II, LLC
- 4.16 First Supplemental Indenture - American Medical Systems Holdings, Inc.
- 4.17 Second Supplemental Indenture - American Medical Systems, Inc.
- 4.18 Third Supplemental Indenture - Generics Bidco II, LLC
- 5 Opinion of Skadden, Arps, Slate, Meagher & Flom LLP
- 12 Statement Regarding Computation of Ratio of Earnings to Fixed Charges
- 21 Subsidiaries of the Registrant
- 23.1 Consent of Independent Registered Public Accounting Firm
- 23.2 Consent of Independent Registered Public Accounting Firm
- 23.3 Consent of Independent Registered Public Accounting Firm
- 25.1 Statement of Eligibility of Trustee, Indenture for 7.00% Senior Notes Due 2020
- 25.2 Statement of Eligibility of Trustee, Indenture for 7% Senior Notes Due 2019
- 25.3 Statement of Eligibility of Trustee, Indenture for 7 1/4% Senior Notes Due 2022
- 99.1 Form of Letter of Transmittal
- 99.2 Form of Letter to Clients
- 99.3 Form of Letter to Brokers
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in this Registration Statement on Form S-4 of our reports dated February 28, 2011 (October 14, 2011 as to Note 21) relating to the consolidated financial statements and financial statement schedule of Endo Pharmaceuticals Holdings Inc. and subsidiaries (the “Company”) and the effectiveness of the Company’s internal control over financial reporting, appearing in the Current Report on Form 8-K of the Company filed on October 14, 2011. We also consent to the reference to us under the heading “Experts” in the Prospectus, which is part of such Registration Statement.
/s/ Deloitte & Touche LLP
Philadelphia, Pennsylvania
October 14, 2011